Compounds > 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Page last updated: 2024-09-02

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and triazinate

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with triazinate in 1 studies

Compound Research Comparison

Studies
(3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione)		Trials
(3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione)		Recent Studies (post-2010)
(3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione)		Studies
(triazinate)		Trials
(triazinate)		Recent Studies (post-2010) (triazinate)
497858151

Protein Interaction Comparison

ProteinTaxonomy3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione (IC50)triazinate (IC50)
nuclear receptor coactivator 3 isoform aHomo sapiens (human)7.475

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arsenau, JC; Blessing, J; Lewis, GC; Slavik, M1

Other Studies

1 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and triazinate

ArticleYear
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
    American journal of clinical oncology, 1982, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Etoposide; Female; Humans; Maytansine; Neoplasm Recurrence, Local; Pelvic Neoplasms; Piperazines; Razoxane; Research Design; Triazines

1982